Infantile hemangiomas usually appear by 4 weeks and stop growing by 5 months; what is the preferred initial treatment?

Infantile hemangiomas usually appear by 4 weeks and stop growing by 5 months; what is the preferred initial treatment?

• A. Intralesional corticosteroids
• B. Laser therapy
• C. Oral propranolol
• D. Elective surgical excision

Answer: (C)

Oral propranolol is the preferred initial treatment for infantile hemangiomas that are proliferating or posing risk to function or appearance. These lesions often begin in the first weeks of life and grow during the proliferative phase, but propranolol directly targets the abnormal vascular growth: it causes rapid vasoconstriction, reduces expression of pro-angiogenic factors like VEGF, and promotes endothelial cell apoptosis, leading to quicker fading and eventual involution of the lesion. This approach is favored because it has a high rate of meaningful improvement with a favorable safety profile when monitored carefully, and it avoids the invasiveness of surgery or the limited efficacy of older therapies. Start dosing around 2 mg per kg per day in divided doses, and monitor for potential side effects such as slowed heart rate, low blood pressure, or low blood sugar. Screen for contraindications (for example, significant asthma or certain heart conditions) and observe the infant after initiation. Intralesional corticosteroids and laser therapy may be used in selected cases, but they are not first-line for initial comprehensive management of a growing lesion. Surgical excision is generally reserved for residual deformity after involution or for lesions causing specific, unmanageable problems.

Oral propranolol is the preferred initial treatment for infantile hemangiomas that are proliferating or posing risk to function or appearance. These lesions often begin in the first weeks of life and grow during the proliferative phase, but propranolol directly targets the abnormal vascular growth: it causes rapid vasoconstriction, reduces expression of pro-angiogenic factors like VEGF, and promotes endothelial cell apoptosis, leading to quicker fading and eventual involution of the lesion.

This approach is favored because it has a high rate of meaningful improvement with a favorable safety profile when monitored carefully, and it avoids the invasiveness of surgery or the limited efficacy of older therapies. Start dosing around 2 mg per kg per day in divided doses, and monitor for potential side effects such as slowed heart rate, low blood pressure, or low blood sugar. Screen for contraindications (for example, significant asthma or certain heart conditions) and observe the infant after initiation.

Intralesional corticosteroids and laser therapy may be used in selected cases, but they are not first-line for initial comprehensive management of a growing lesion. Surgical excision is generally reserved for residual deformity after involution or for lesions causing specific, unmanageable problems.